- Home
- IVP vs GRI Comparison
IVP vs GRI Comparison
Compare IVP & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- GRI
- Stock Information
- Founded
- IVP 2020
- GRI 2018
- Country
- IVP United States
- GRI United States
- Employees
- IVP N/A
- GRI N/A
- Industry
- IVP Diversified Commercial Services
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- GRI Health Care
- Exchange
- IVP Nasdaq
- GRI Nasdaq
- Market Cap
- IVP 3.3M
- GRI 3.4M
- IPO Year
- IVP 2023
- GRI N/A
- Fundamental
- Price
- IVP $0.78
- GRI $1.28
- Analyst Decision
- IVP
- GRI Strong Buy
- Analyst Count
- IVP 0
- GRI 2
- Target Price
- IVP N/A
- GRI $22.00
- AVG Volume (30 Days)
- IVP 489.4K
- GRI 282.4K
- Earning Date
- IVP 08-13-2025
- GRI 08-13-2025
- Dividend Yield
- IVP N/A
- GRI N/A
- EPS Growth
- IVP N/A
- GRI N/A
- EPS
- IVP N/A
- GRI N/A
- Revenue
- IVP $15,399,751.00
- GRI N/A
- Revenue This Year
- IVP N/A
- GRI N/A
- Revenue Next Year
- IVP N/A
- GRI N/A
- P/E Ratio
- IVP N/A
- GRI N/A
- Revenue Growth
- IVP N/A
- GRI N/A
- 52 Week Low
- IVP $0.63
- GRI $1.10
- 52 Week High
- IVP $255.00
- GRI $30.43
- Technical
- Relative Strength Index (RSI)
- IVP 34.42
- GRI 36.89
- Support Level
- IVP $0.71
- GRI $1.93
- Resistance Level
- IVP $0.78
- GRI $2.20
- Average True Range (ATR)
- IVP 0.08
- GRI 0.20
- MACD
- IVP 0.02
- GRI -0.04
- Stochastic Oscillator
- IVP 38.97
- GRI 2.24
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.